Key result
Preventive warfarin and rivaroxaban reduce neurologic severity and spinal cord inflammation in experimental autoimmune encephalomyelitis.
Answers are grounded in this paper and cite their sources.
BACKGROUND: In multiple sclerosis, coagulation factors have been shown to modulate inflammation. In this translational study, we investigated whether long-term anticoagulation with warfarin or rivaroxaban has beneficial effects on the course of autoimmune experimental encephalomyelitis (EAE). METHODS: . Stable anticoagulation was maintained throughout the entire experiment. Mice without anticoagulation treated with the vehicle only were used as controls. The neurological deficit was recorded during the course of EAE, and histopathological analyses of inflammatory lesions were performed. RESULTS: In preventive settings, both treatment with warfarin and rivaroxaban reduced the maximum EAE score as compared to the control group and led to a reduction of inflammatory lesions in the spinal cord. In contrast, therapeutic treatment with warfarin had no beneficial effects on the clinical course of EAE. Signs of intraparenchymal hemorrhage at the site of the inflammatory lesions were not observed. CONCLUSION: We developed long-term anticoagulation models that allowed exploring the course of EAE under warfarin and rivaroxaban treatment. We found a mild preventive effect of both warfarin and rivaroxaban on neurological deficits and local inflammation, indicating a modulation of the disease induction by anticoagulation.
No takes yet. Share an insight, caveat, or question.
Stolz et al. (2017) studied Experimental autoimmune encephalomyelitis (EAE). Warfarin and rivaroxaban vs. Vehicle control was evaluated on Maximum EAE score and inflammatory lesions. Preventive treatment with warfarin and rivaroxaban reduced maximum EAE scores and inflammatory spinal cord lesions compared to vehicle control in a mouse model.
Synapse has enriched 10 related papers. Consider them for comparative context: